NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
Cell TherapyClinical Result
SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients.
The additional Phase 1 SNK01 trial data suggest clinical activity regarding cognitive function in patients with advanced Alzheimer’s disease in addition to previously disclosed positive effects on amyloid protein and neuroinflammation biomarkers.
March 25, 2024 -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (“NK”) cell therapeutics, today presented additional Phase 1 clinical trial data on the use of its investigational autologous NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the Tau2024 Global Conference in Washington, D.C.
The presentation contained data from an abstract entitled, “Beneficial Effect on CSF and Plasma Tau Proteins and Cognitive Function in Alzheimer’s Disease Subjects Treated with Expanded Non-Genetically Modified Autologous Natural Killer Cells (SNK01).” In this Phase 1 study, SNK01 was administered intravenously (“IV”) every three weeks for a total of four treatments using a 3+3 dose escalation design (1, 2, and 4 x 109 cells) in patients with either mild, moderate, or severe AD (Median MMSE of 14). Cognitive assessments and CSF/plasma pTau217 and pTau181 analyses were performed at baseline and at 1 and 12 weeks after the final dose. The primary endpoint was safety and secondary endpoints included changes in cognitive assessments and biomarker levels.
“The data presented today demonstrate additional beneficial effects of SNK01 for the treatment of Alzheimer’s disease,” commented Paul Y. Song, M.D., CEO of NKGen. “The data from this Phase 1 trial further validates the ability of SNK01 to improve pTau, amyloid Aβ42/40, and alpha-synuclein biomarkers as well as improving cognitive scores, consistent with what we have previously observed. While the results were positive, the Phase 1 trial was a dose-escalation trial that only administered four total doses over 11 weeks. However, our Phase 1/2a SNK01 trial in moderate Alzheimer’s patients, initiated in December 2023, utilizes a 50% higher dose than the highest dose administered in the prior Phase 1, and prolonged dosing regimen for over one year in which we expect to show an even greater clinical benefit. We are excited to continue our research with the goal of offering our NK cell therapy to patients with Alzheimer’s disease who are in need of disease modifying treatments.”
Highlights from the Presentation:
Of the 11 patients enrolled, 10 were evaluable – median MMSE was 14.
SNK01 given via a simple IV appears to cross the blood brain barrier to improve Aβ42/40, Tau, and alpha-synuclein protein levels in CSF.
Despite 70% of patients treated at relatively low doses of SNK01, at one-week post-treatment (week 11):
50–70% of all enrolled patients in the trial had either stable or improved CDR-SB, ADAS-Cog and/or MMSE scores including one patient whose MMSE score improved from 14 to 23.
90% had either stable or improved ADCOMS scores.
50% of patients had a decrease in CSF pTau217.
80% had stable/decreased CSF pTau181 compared to baseline values.
30% had a decrease in plasma pTau217.
40% had a decrease in plasma pTau181.
Where data were available, this decrease continued through week 22 (12 weeks after the last dose) for CSF pTau217 for all patients (n=4), for CSF pTau181 for 5/7 patients, for plasma pTau217 for 2/3 patients, and for plasma pTau181 for 3/4 patients.
At week 11, the percent of patients with a stable/improved ADCOMS score who also had a decrease in CSF pTau was 56% for pTau217 and 78% for pTau181.
No treatment related adverse events were observed.
SNK01 appears safe and well tolerated and the data suggest SNK01 may have potential clinical activity in AD while also reducing CSF and plasma Tau protein levels. A larger trial with a higher dosing/duration was initiated in the U.S. in 2023.
A copy of the abstract and presentation materials will be available on the Scientific Publications page of the Company’s website at https://nkgenbiotech.com/ once the presentation has concluded. Previously disclosed Phase 1 data on the positive effects of SNK01 on amyloid and neuroinflammation biomarkers, which are not included in this Tau-focused conference presentation, can also be found on the Scientific Publications page.
About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
The content above comes from the network. if any infringement, please contact us to modify.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.